AAPG
Ascentage Pharma Group International Co., Ltd.
NASDAQ · Healthcare · Biotechnology · CN
$15.36
−0.07%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$15.52
From 52W high−56.68%
Volume3617.00
Market cap$1.43B
P/E (TTM)—
P/S (TTM)15.1x
Div yield—
Key dataOct 19, 2026
Open
$15.52
From 52W high
−56.68%
Volume
3617.00
Market cap
$1.43B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.5x
P/E (TTM)
—
RSI (14)
47.2
MomentumView details →
1D Return
−0.07%
YTD Return
−42.05%
SummaryUpdated Jun 1, 2026
Ascentage Pharma Group International (HKEX:6855) is a clinical-stage biotechnology company founded in 2009 and headquartered in Suzhou, China. The company focuses on developing innovative therapies for cancer treatment, chronic hepatitis B virus infections, and age-related diseases, primarily serving the Chinese mainland market. As a relatively young biotech firm that went public in January 2025, Ascentage operates in the highly specialized field of oncology drug development, with a particular emphasis on targeting specific protein interactions that can restore normal cell death processes in cancer cells.
Similar companies
Latest newsMore news →
Yang Dajun, executive director and board chairman of Ascentage Pharma (06855), bought a total of 38,630 shares on-market on September 23, 24 and 25 at an average price of HK$29.95 per share for about HK$1.1571 million, equal to roughly 0.01% of total issued share capital.21d agoAscentage Pharma appointed Dr. Faical Miyara as Chief Business Officer.61d ago